An independent global coalition of stakeholders has recognised the need to create an efficient, measurable and reliable meta-framework to integrate the voice of the patient across the lifecycle of medicines development. Members of Patient Focused Medicines Development (PFMD) discuss the importance of creating a standardised patient engagement framework that directly benefits patients in a recent video.

PFMD member Jan Geissler, Director of the European Patients’ Academy on Therapeutic Innovation (EUPATI) explains: “We need to work on a systematic level to engage and involve patients across the whole drug development lifecycle so that we can think about the right priorities for research and involve patients in the planning and conduct of research. We need to start working on something that is tangible and useable that will benefit patients.”

Marc Boutin, Chief Executive Officer at National Health Council says: ‘We want to have treatments that really reflect the values that are important to patients. PFMD has the ability to transform how we develop treatments to partner with patients and address the issues that are most important to them throughout the continuum of drug development.”

Paul Robinson Director of Patient Perspectives at Merck Sharp & Dohme Ltd. says: ‘We started off developing medicines in a fairly paternalistic ‘we know best’ way. We are now moving into an era where patients are telling us what they want and we need to react to that.”

PFMD member Nicola Bedlington, Secretary General of the European Patients’ Forum says: ‘Patients throughout the world have the opportunity to contribute to good medicine development’

Marylin Metcalf, Senior Director, Benefit Risk Evaluation at GlaxoSmithKline: ‘Patients want to be at the table more as equal partners. All of us are here because we have a fundamental yearning to make a difference to people’s lives”

Sarah Krug, Executive Director of CANCER101: “It is critical that we start to engage patients by ensuring that their voices are heard and that their issues are addressed and that we include them from the beginning so that we are effectively co-designing the future of healthcare for patients with patients”

Watch the video interview to find out more:


PFMD welcomes membership from institutions, organisations and enterprises committed to better patient engagement in the lifecycle of medicines and a better future for patients. Join us and help shape the patient engagement landscape.